Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0SEPSZ
|
|||||
---|---|---|---|---|---|---|
ADC Name |
CN106459205B ADC-2
|
|||||
Synonyms |
CN106459205B_ADC-2
Click to Show/Hide
|
|||||
Organization |
MedImmune LLC
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 1 Indication(s)
Prostate cancer [ICD11:2C82]
Investigative
|
|||||
Drug-to-Antibody Ratio |
1.98
|
|||||
Antibody Name |
Anti-EPHA2 mAb 1C1
|
Antibody Info | ||||
Antigen Name |
Ephrin type-A receptor 2 (EPHA2)
|
Antigen Info | ||||
Payload Name |
Undisclosed
|
|||||
Linker Name |
CN106459205B ADC-2 linker
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Effective Concentration (EC50) | 42.20 ng/mL | Positive EPHA2 expression (EPHA2+++/++) | ||
Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
In Vitro Model | Prostate carcinoma | DU145 cells | CVCL_0105 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.